|Submission Date||Wed,Mar 25,2015|
|Acceptance Date||: Tue,Apr 10,2015|
|Publishing Date||: Wed,Apr 27,2015|
|Type of Paper||: Research Article|
|Mode of Access||: Open Access|
|Author||:Youssef Moutaouakkil1, Hicham Chesmi 1, Mohamed Reda Tagajdid2, Mohammed Sbaai1, Safae Elkochri1, Rachid Abi1, Saad Mrani1, 2|
|Affiliation||1: Department of Virology, Mohammed V Military Teaching Hospital Mohamed V-university, Rabat, Morocco 2: Human and molecular virology department, Military teaching hospital Med V, Mohamed V- university, Rabat, Morocco|
The objective of this study was to determine the seroprevalance of human immunodeficiency virus in Morocco. This will establish public health priorities to adopt appropriate prevention policies. The HIV status of patients was determined by the Enzygnost® HIV Integral II kit, ELISA on BEP2000® Advanced PLC Siemens of Virology at the HMIMV Rabat. The specificity of the kit is 99.9%. Confirmation of positive Elisa test is performed by the Enzygnost® Kit HIV-1/2 Western blot. Quantification of viral load by real-time RT-PCR was performed on the COBAS AmpliPrep / COBAS TaqMan48® HIV-1 (Roche Diagnostics) with 20 copies / ml detection limit. A total of 7293 individuals were tracked. 40 people were screened HIV positive, a prevalence of 0.55% with a complete profile. The distribution according to sex was on behalf of men (67.5% in men and 32.5% in women) with a sex ratio (male / female) of 2.08. Through this study, we confirm that the prevalence of infection with virus type 1 human immunodeficiency is 0.55%, which is still low prevalence although the risk of rapid change is not deviate.